ATRY Atrys Health, S.A.

BME · ES · Healthcare · Biotechnology · atryshealth.com

2.565EUR-0.19%Mkt Cap: 211.66M $P/E: —Today

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medic…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap211.66M USD

Enterprise Value327.29M USD

Revenue (TTM)160.52M USD

Gross Profit66.68M USD

Net Income (TTM)-109.02M USD

Revenue/Share1.95 EUR

Last Price2.565 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees763

CountryES

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)16.74

PEG—

EV/EBITDA1209.25

EV/Revenue2.04

P/S1.32

P/B1.33

EPS (TTM)-0.63

EPS (Forward)0.15

52W Range

2.31020% of range3.590

52W High3.590 EUR

52W Low2.310 EUR

Profitability

Gross Margin43.51%

Oper. Margin-0.90%

EBITDA Margin0.17%

Profit Margin-71.13%

ROE-66.05%

ROA-20.30%

Growth

Revenue Growth9.40%

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.69M USD

CapEx (TTM)13.61M USD

FCF Margin8.65%

FCF Yield6.56%

Net Debt114.77M USD

Net Debt/EBITDA424.04

Balance Sheet

Debt/Equity1.70

Current Ratio0.47

Quick Ratio0.39

Book Value/Sh1.94 EUR

Cash/Share0.17 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)4.833 EUR

Upside (mean)+88.4%

Target Range4.000 EUR – 5.500 EUR

4.000+88.4% to mean5.500

# Analysts3

Ownership

Shares Out.75.92M

Float42.47M

Insiders56.77%

Institutions11.07%

Technical

SMA 502.622 (-2.2%)

SMA 2002.758 (-7.0%)

Beta0.57

S&P 52W Chg14.58%

Avg Vol (30d)47.87K

Avg Vol (10d)32.88K

Technical Indicators

RSI (14)42.0

MACD0.0111

MACD Signal0.0375

MACD Hist.-0.0265

BB Upper2.975 EUR

BB Middle2.705 EUR

BB Lower2.435 EUR

BB Width19.98%

ATR (14)0.1011 EUR

Vol Ratio (20d)0.88x